Drugs for pre-osteoporosis: prevention or disease mongering?
Abstract
After looking at data used to support treatment of women with slightly lowered bone mineral density, Pablo Alonso-Coello and colleagues argue thatproponents have overstated the benefits and underplayed the harmsKeywords
This publication has 20 references indexed in Scilit:
- Effects of risedronate on fracture risk in postmenopausal women with osteopeniaOsteoporosis International, 2007
- An Approach to Identifying Osteopenic Women at Increased Short-term Risk of FractureArchives of internal medicine (1960), 2004
- Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial11Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.Bone, 2003
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- The Relationship Between Bone Density and Incident Vertebral Fracture in Men and WomenJournal of Bone and Mineral Research, 2002
- Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomesStatistics in Medicine, 2002
- Osteoporosis in postmenopausal women: diagnosis and monitoring.2001
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracturesBMJ, 1996
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.1994